EUVIMEDEUVIMED entdecken
Crossref

Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia‐Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT

Jordi Esteve iD, Arnon Nagler iD, Myriam Labopin, Jurjen Versluis, Jaime Sanz iD, Tobias Gedde-Dahl, David Burns, Mieke Roeven, Hélène Labussière-Wallet, Peter von dem Borne iD, Gwendolyn van Gorkom, Nathalie Contentin und 5 weitere

American Journal of Hematology · 2025

DOI: 10.1002/ajh.27647 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Jordi Esteve und 16 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation, Myelodysplastic Syndromes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients (pts) with myelodysplasia‐related AML (MR‐AML) are now genetically recategorized, with three different groups in the International Consensus Classification: AML with mutated TP53 (TP53‐AML), with myelodysplasia‐related gene mutations (MR‐GM AML), and with myelodysplasia‐related cytogenetic abnormalities (MR‐CG AML). Moreover, TP53‐AML is determined by the presence of an additional complex karyotype (TP53‐mut CK and non‐CK AML, respectively). Nonetheless, the relevance of this classification to transplantation outcomes is largely unknown. We analyzed the outcomes of pts. with MR‐AML undergoing allogeneic hematopoietic cell transplantation in first complete remission between 2010 and 2022 according to these genetic categories. Overall, 1152 patients were identified: 379 (33%), 328 (28%), 246 (21%), and 199 (17%) with MR‐GM, TP53‐mut CK, MR‐CG, and TP53‐mut non‐CK AML, respectively. Median age was 60 years; median year of transplant was 2020. Unrelated donors and reduced‐intensity conditioning were used in 65% and 61% of cases, respectively. Outcomes differed markedly among genetic categories, with an increasing relapse incidence (20.2%, 29.2%, 44.6%, and 57.6% at 2 years), and decreasing LFS (60%, 55.3%, 40.6%, and 20.2% at 2 years), overall survival (65.7%, 60.1%, 47.1%, and 24.5% at 2 years), and graft‐versus‐host disease‐free, relapse‐free survival (46.9%, 39.5%, 31.9%, and 13.2% at 2 years) in MR‐GM, MR‐CG, TP53‐mut non‐CK, and TP53‐mut CK AML, respectively. These differences were confirmed in the multivariate analysis (hazard ratio for LFS: 0.21, 0.33 and 0.61 in MR‐GM, MR‐CG, and TP53‐mut non‐CK, with respect to reference TP53‐mut CK AML group). This study confirms the strong impact of genetic grouping of MR‐AML on transplant outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHematopoietic Stem Cell TransplantationMyelodysplastic SyndromesHumansMiddle AgedMaleFemaleRetrospective StudiesAgedAdultTransplantation, HomologousMutationYoung AdultTransplantation ConditioningAdolescentTumor Suppressor Protein p53Allografts

Stichwörter der Autor:innen

acute myeloid leukemiaallogeneic hematopoietic cell transplantationmutated TP53myelodysplasia‐related cytogenetic abnormalitymyelodysplasia‐related gene mutation

Substanzen

Tumor Suppressor Protein p53

Autor:innen und Institutionen

  • Hematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
  • Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel.
  • EBMT Paris Study Office; Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Sorbonne University, Paris, France.
  • Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands.
  • Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
  • Department de Medicina de la Universitat de València, CIBERONC, Instituto Carlos III, Madrid, Spain.

ORCID-Profile: Jordi Esteve, Arnon Nagler, Jaime Sanz, Peter von dem Borne

Zitieren

APA

Esteve, J., Nagler, A., Labopin, M., Versluis, J., Sanz, J., Gedde-Dahl, T., Burns, D., Roeven, M., Labussière-Wallet, H., von dem Borne, P., van Gorkom, G., Contentin, N., Neubauer, A., Wagner-Drouet, E. M., Kröger, N., Mohty, M., & Ciceri, F. (2025). Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia‐Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT. American Journal of Hematology. https://doi.org/10.1002/ajh.27647

Vancouver

Esteve J, Nagler A, Labopin M, Versluis J, Sanz J, Gedde-Dahl T, et al. Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia‐Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT. American Journal of Hematology. 2025. doi:10.1002/ajh.27647

BibTeX
@article{Esteve2025,
  author = {Esteve, Jordi and Nagler, Arnon and Labopin, Myriam and Versluis, Jurjen and Sanz, Jaime and Gedde-Dahl, Tobias and Burns, David and Roeven, Mieke and Labussière-Wallet, Hélène and von dem Borne, Peter and van Gorkom, Gwendolyn and Contentin, Nathalie and Neubauer, Andreas and Wagner-Drouet, Eva Maria and Kröger, Nicolaus and Mohty, Mohamad and Ciceri, Fabio},
  title = {Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia‐Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT},
  journal = {American Journal of Hematology},
  year = {2025},
  doi = {10.1002/ajh.27647}
}
Kostenlos starten →